· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc.
Contact the company for a copy of any references, attachments or enclosures.
November 18, 2010
Subject: Important new restrictions on the use of rosiglitazone products due to information on heart-related events (AVANDIA®, AVANDAMET® and AVANDARYL®)
GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of important new restrictions on the use of AVANDIA® (rosiglitazone), AVANDAMET® (contains both rosiglitazone and metformin), and AVANDARYL® (contains both rosiglitazone and glimepiride) for the treatment of type 2 diabetes mellitus.
Based on a Health Canada review of recent data suggesting an elevated risk of cardiovascular (heart-related) events in patients treated with AVANDIA®, the consumer and prescriber sections of the Canadian Product Monographs for rosiglitazone-containing products have been updated and include new usage restrictions. These restrictions and important information for patients are described below.
AVANDIA®/AVANDAMET®/AVANDARYL® is now indicated only in patients with type 2 diabetes mellitus when all other diabetes medicines taken orally (by mouth) have not lowered blood sugar enough, or are not appropriate.
Also please note that a new boxed warning has been added to the Canadian Product Monographs. In the Consumer Information section, this boxed warning includes the following information:
GSK has sent a letter to Canadian healthcare professionals informing them of this new safety information. You may view this letter on the Canadian Web site of GSK or on Health Canada's MedEffect Web site.
Doctors have been advised to counsel new and currently treated patients on the risks and benefits of starting and/or continuing treatment with AVANDIA®/AVANDAMET®/AVANDARYL® and will be asking patients to read and sign a form indicating that they understand the heart-related risks of AVANDIA®/AVANDAMET®/AVANDARYL®. The informed consent form, Product Monographs and Consumer Information for AVANDIA®/AVANDAMET®/ AVANDARYL® are available on the Canadian Web site of GSK. The Product Monographs will also be available on Health Canada's Drug Product Database.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving AVANDIA®, AVANDAMET® and AVANDARYL® should be reported to GlaxoSmithKline Inc. or Health Canada at the following address:
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Tel.: 1-800-387-7374
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
For media enquiries, please contact GSK Corporate Communications, 905-819-3363.
Sincerely,
original signed by
Dr. Tjark Reblin, MD, MBA
Vice President, Medical Division and Chief Medical Officer
GlaxoSmithKline Inc.
Avandia®, Avandamet® and Avandaryl® are registered trademarks, used under license by GlaxoSmithKline Inc.
This HTML document is not a form. Its purpose is to display the information as found on the form for viewing purposes only. If you wish to use the form, you must use the alternate format below.
AVANDIA® /AVANDAMET®/AVANDARYL®
Patient Informed Consent
My doctor has recommended one of the following medicines to treat my diabetes (please check one of the boxes below, as appropriate):
Please read this Patient Informed Consent ("Consent") and the individual Consumer Information for AVANDIA®/AVANDAMET®/AVANDARYL® and discuss any questions or concerns with your doctor before you sign this Consent.
Do not sign this Consent and do not take AVANDIA®/AVANDAMET®/AVANDARYL® if there is anything you do not understand about the information you have received.
I am aware that:
My doctor has explained the above to me, I have been given time to read this Consent and the individual Consumer Information for AVANDIA®/AVANDAMET®/AVANDARYL® carefully, and to discuss it with my doctor. I now authorize my doctor to continue/begin my treatment with AVANDIA®/AVANDAMET®/AVANDARYL®.
Patient or Legally Appointed Guardian signature lines are below. AVANDIA®/ AVANDAMET®/AVANDARYL® are not recommended for use in people under the age of 18.
Patient (and Legally Appointed Guardian if applicable) Name(s)
Please Print:
Patient / Legally Appointed Guardian Signature:
Date:
® AVANDIA, AVANDAMET, and AVANDARYL are registered trademarks, used under license by GlaxoSmithKline Inc.